Every 8-K that IB ACQUISITION CORP (IBACR) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow IBACR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full IBACR filings page.
IB Acquisition Corp. obtained stockholder approval to extend the deadline to complete its initial business combination from March 28, 2026 to September 28, 2026 through amendments to its trust agreement and articles of incorporation. If no deal is completed by September 28, 2026, the trust account will be liquidated under specified redemption and liquidation procedures, with no trust amounts used to pay dissolution expenses. The changes also clarify that trust funds generally remain locked except for interest used to pay franchise and income taxes, and reinforce public stockholders’ rights to redeem their shares in connection with key charter amendments affecting redemptions or the business combination timeline.
IB Acquisition Corp. reported the results of a special stockholder meeting and related redemptions of its common stock. Stockholders owning 5,077,821 shares, or about 88.46% of shares outstanding as of the February 11, 2026 record date, were present or represented by proxy.
Each proposal voted on at the meeting received 5,007,821 votes for and 70,000 against, with no abstentions or broker non-votes, so all proposals were approved. Separately, holders of 731,741 shares chose to redeem their shares for cash at approximately $10.78 per share from the company’s trust account.
These redemptions will remove about $7.9 million from the trust account, leaving approximately $8.2 million remaining. The remaining trust balance may change to reflect tax withdrawals.
IB Acquisition Corp. reports that its prospective merger partner, GNQ Insilico Inc., has entered a Joint Initiative Agreement and Joint Marketing Attachment with a Fortune 100 global technology company. The two-year, non-exclusive collaboration will jointly market AI-driven drug discovery and precision medicine solutions worldwide, combining GNQ’s proprietary AI platforms with the partner’s consulting, cloud, and quantum computing capabilities.
The report also reiterates a proposed business combination between IB Acquisition and GNQ. IB Acquisition plans to file a Form S-4 registration statement with the SEC, including a joint proxy statement/prospectus that will be sent to its stockholders in connection with the transaction.
IB Acquisition Corp. has entered a definitive business combination agreement to acquire GNQ Insilico Inc., valuing GNQ at US$500,000,000 plus potential revenue and share price earnouts. GNQ will become a Nasdaq-listed AI- and quantum-driven drug development company following a plan of arrangement under Canadian law.
The transaction is expected to provide approximately US$15 million of proceeds to GNQ through cash in IB Acquisition’s trust account and a PIPE of up to US$10 million, alongside a separate bridge financing of up to US$2,000,000 in 10% secured convertible notes and warrants. Closing, targeted for the third quarter of 2026, is subject to shareholder approvals, court orders, regulatory clearances, a minimum of US$5,000,001 in IB Acquisition net tangible assets, and at least US$15.0 million of available cash.